Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
2002 1
2003 1
2012 2
2013 3
2014 3
2015 1
2016 3
2017 3
2018 5
2019 2
2020 4
2021 5
2022 1
2023 7
2024 5
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population.
Rimini M, Fornaro L, Rizzato MD, Antonuzzo L, Rossari F, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Chon HJ, Braconi C, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Salani F, De Rosa A, Lavacchi D, Foti S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Zanuso V, Masi G, Lonardi S, Rimassa L, Casadei-Gardini A. Rimini M, et al. Among authors: lucchetti j. Eur J Cancer. 2024 Sep;208:114199. doi: 10.1016/j.ejca.2024.114199. Epub 2024 Jun 30. Eur J Cancer. 2024. PMID: 39002348
SEPN1-related myopathy depends on the oxidoreductase ERO1A and is druggable with the chemical chaperone TUDCA.
Germani S, Van Ho AT, Cherubini A, Varone E, Chernorudskiy A, Renna GM, Fumagalli S, Gobbi M, Lucchetti J, Bolis M, Guarrera L, Craparotta I, Rastelli G, Piccoli G, de Napoli C, Nogara L, Poggio E, Brini M, Cattaneo A, Bachi A, Simmen T, Calì T, Quijano-Roy S, Boncompagni S, Blaauw B, Ferreiro A, Zito E. Germani S, et al. Among authors: lucchetti j. Cell Rep Med. 2024 Mar 19;5(3):101439. doi: 10.1016/j.xcrm.2024.101439. Epub 2024 Feb 22. Cell Rep Med. 2024. PMID: 38402623 Free PMC article.
Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapy.
Vitiello F, Vivaldi C, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Salani F, Kim JW, Rapposelli IG, Tamburini E, Rimini M, Prinzi FL, Satake T, Peeters F, Pressiani T, Lucchetti J, Abidoye O, Gallio C, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Qaisar A, Pastorino A, Castet F, Yoo C, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Parisi A, Diana A, Couto N, Chan SL, Garajova I, Roque R, Ikeda M, Niger M, Tonini G, Himmelsbach V, Landriscina M, Masi G, Vogel A, Lonardi S, Fornaro L, Rimassa L, Casadei-Gardini A, Adeva J, Spinelli GP, Personeni N, Rodriguez MG, Leo S, Alvim CM, Farinea G, Genovesi V, De Rosa A, Lavacchi D, Camera S, Dekervel J, Balsano R, Kang M, Tesini G, Esposito L, Boccancino A, Ahcene Djaballah S, Bekaii-Saab T. Vitiello F, et al. Among authors: lucchetti j. Oncology. 2025 Aug 14:1-26. doi: 10.1159/000546856. Online ahead of print. Oncology. 2025. PMID: 40815107
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer.
Castet F, Fabregat-Franco C, Bridgewater J, Kim JW, Rimini M, La Casta A, Lamarca A, Kang M, Salani F, Castillo A, Lopes A, Hyung J, Rimassa L, Adeva J, López-Valbuena D, Basagaña-Farres M, Vaja S, Mak KM, Tian TV, Muñoz A; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD); Casadei-Gardini A; DURVABTC Group; Yoo C, Valle JW, Macarulla T. Castet F, et al. J Hepatol. 2025 Nov;83(5):1102-1115. doi: 10.1016/j.jhep.2025.05.020. Epub 2025 Jun 3. J Hepatol. 2025. PMID: 40473034
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D Index.
Persano M, Rimini M, Salani F, Prinzi FL, Nichetti F, Saborowski A, Antonuzzo L, Passeri L, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Corallo S, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Fornaro L, De Rosa A, Lanzetta I, Balsano R, Lavacchi D, Camera S, Ikeda M, Dekervel J, Niger M, Tesini G, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Ferrara M, Himmelsbach V, Landriscina M, Djaballah SA, Masi G, Vogel A, Lonardi S, Rimassa L, Casadei-Gardini A. Persano M, et al. Among authors: lucchetti j. Liver Int. 2025 Jul;45(7):e70181. doi: 10.1111/liv.70181. Liver Int. 2025. PMID: 40525496
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population.
Prinzi FL, Salani F, Camera S, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Gallio C, Tamberi S, Finkelmeier F, Giordano G, Chiara P, Chon HJ, Braconi C, Qaisar A, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Polito MG, Di Giacomo E, Farinea G, Bartalini L, Grelli G, De Rosa A, Lavacchi D, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Tesini G, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Bekaii-Saab T, Fornaro L, Masi G, Vogel A, Lonardi S, Rimini M, Rimassa L, Casadei-Gardini A. Prinzi FL, et al. Among authors: lucchetti j. Int J Cancer. 2025 Nov 15;157(10):2092-2102. doi: 10.1002/ijc.70009. Epub 2025 Jul 11. Int J Cancer. 2025. PMID: 40641448 Free PMC article.
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab.
Pirrone C, Malapelle U, Pepe F, Lo Prinzi F, Nichetti F, Saborowski A, Antonuzzo L, Camera S, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Qaisar A, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Corallo S, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Salani F, De Grandis C, Lavacchi D, Persano M, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, De Cobelli F, Ratti F, Daniel F, Tesini G, Masi G, Vogel A, Lonardi S, Rimini M, Fornaro L, Rimassa L, Casadei-Gardini A. Pirrone C, et al. Among authors: lucchetti j. Eur J Cancer. 2025 Nov 17;230:116035. doi: 10.1016/j.ejca.2025.116035. Epub 2025 Oct 3. Eur J Cancer. 2025. PMID: 41076988
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population.
Lo Prinzi F, Salani F, Rimini M, Rizzato MD, Antonuzzo L, Camera S, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Melo Alvim C, Roque R, Fornaro L, De Rosa A, Lavacchi D, Rossari F, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Viola MG, Silvestro L, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Ahcene Djaballah S, Zanuso V, Masi G, Lonardi S, Rimassa L, Casadei-Gardini A. Lo Prinzi F, et al. Among authors: lucchetti j. Oncologist. 2025 Mar 10;30(3):oyae256. doi: 10.1093/oncolo/oyae256. Oncologist. 2025. PMID: 39427227 Free PMC article.
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study.
Rimini M, Fornaro L, Prinzi FL, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Salani F, De Rosa A, Lavacchi D, Camera S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Corallo S, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Vitiello F, Himmelsbach V, Landriscina M, Djaballah SA, Tesini G, Masi G, Vogel A, Lonardi S, Rimassa L, Casadei-Gardini A. Rimini M, et al. Among authors: lucchetti j. Int J Cancer. 2025 Sep 15;157(6):1246-1259. doi: 10.1002/ijc.35481. Epub 2025 May 19. Int J Cancer. 2025. PMID: 40387725
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population.
Rimini M, Fornaro L, Lo Prinzi F, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Jae Chon H, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Corallo S, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Salani F, De Rosa A, Lavacchi D, Camera S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Zanuso V, Malapelle U, Pepe F, Masi G, Vogel A, Lonardi S, Rimassa L, Casadei-Gardini A. Rimini M, et al. Among authors: lucchetti j. J Natl Cancer Inst. 2025 Oct 1;117(10):2029-2043. doi: 10.1093/jnci/djaf155. J Natl Cancer Inst. 2025. PMID: 40608977
56 results